Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction

International Journal of Cardiology

Volumn 105, Issue 1, 2005, Pages 67-73

  Nakaya, Reiko ^a   Uzui, Hiroyasu ^a   Shimizu, Hiromasa ^a   Nakano, Akira ^a   Mitsuke, Yasuhiko ^a   Yamazaki, Taketoshi ^a   Ueda, Takanori ^a   Lee, Jong Dae ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Matrix metalloproteinase; Myocardial infarction; Pravastatin; Remodeling

Indexed keywords

ANTILIPEMIC AGENT; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; FEMALE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICULOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM EXPOSURE; MALE; MEASUREMENT; PRIORITY JOURNAL; REPERFUSION; STATISTICAL SIGNIFICANCE;

AGED; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; STROKE VOLUME; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; TRIGLYCERIDES; VASODILATION;

EID: 26044477451     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.12.024     Document Type: Article

References (28)

1. M.A. Pfeffer, and E. Braunwald Ventricular remodeling after myocardial infarction: experimental observations and clinical implications Circulation 81 1990 1161 1172
2. H. Nagase, and J.F. Woessner Jr. Matrix metalloproteinases J Biol Chem 274 1999 21491 21494
3. T. Inoue, T. Kato, K. Takayanagi, T. Uchida, I. Yaguchi, and H. Kamishirado Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome Am J Cardiol 92 2003 1461 1464
4. J.P.M. Cleutjens, J.C. Kandala, E. Guarda, R.V. Guntaka, and K.T. Weber Regulation of collagen degradation in the rat myocardium after infarction J Mol Cell Cardiol 27 1995 1281 1292
5. S. Sato, M. Ashraf, R.W. Millard, H. Fujiwara, and A. Schwartz Connective tissue changes in early ischemia of porcine myocardium: an ultrastructural study J Mol Cell Cardiol 15 1983 261 275
6. H. Kai, H. Ikeda, H. Yasukawa, M. Kai, Y. Seki, and F. Kawahara Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute myocardial syndrome J Am Coll Cardiol 32 1998 368 372
7. S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, and T. Kubota Targeted deletion of matrix metalloproteinase-2 attenuates early left ventricular rupture and late remodeling after experimental myocardial infarction Am J Physiol: Heart Circ Physiol 285 2003 H1229 H1235
8. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S) Lancet 344 1994 1383 1389
9. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001 1009
10. S. Hayashidani, H. Tsutsui, T. Shiomi, N. Suematsu, S. Kinugawa, and T. Ide Fluvastatin, a 3-hydroxy-3-methylgulutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 105 2002 868 873
11. N. Fujimoto, N. Mouri, K. Iwata, E. Ohuchi, Y. Okada, and T. Hayakawa A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies Clin Chim Acta 221 1993 91 103
12. N. Fujimoto, J. Zhang, K. Iwata, T. Shinya, Y. Okada, and T. Hayakawa A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies Clin Chim Acta 220 1993 31 45
13. D.G. Greene, R. Carlisle, C. Grant, and I.L. Bunnell Estimation of left ventricular volume by one-plane cineangiography Circulation 35 1967 61 69
14. G. Pasterkamp, A.H. Shoneveld, D.J. Hijnen, D.P. de Kleijn, H. Teepen, and A.C. van der Wal Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery Atherosclerosis 150 2000 245 253
15. Y. Iwanaga, T. Aoyama, Y. Kihara, Y. Onozawa, T. Yoshida, and S. Sasayama Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats J Am Coll Cardiol 39 2002 1384 1391
16. F.G. Spinale, M.L. Coker, C.V. Thomas, J.D. Walker, R. Mukherjee, and L. Hebbar Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function Circ Res 82 1998 482 495
17. V.S. Mujumdar, L.M. Smily, and S.C. Tyagi Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength Int J Cardiol 79 2001 277 286
18. J. Kjekshus, T.R. Pedersen, A.G. Olsson, O. Faergeman, and K. Pyorala The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J Card Fail 3 1997 249 254
19. J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 2001 982 985
20. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown, and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 1992 669 677
21. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 327 1992 293 302
22. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
23. U. Ikeda, M. Shimpo, R. Ohki, H. Inaba, M. Takahashi, and K. Yamamoto Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells Hypertension 36 2000 325 329
24. D.N. Tziakas, G.K. Chalikias, J.T. Parissis, E.I. Hatzinikolaou, E.D. Papadopoulos, and G.A. Tripsiannis Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration Int J Cardiol 94 2004 269 277
25. J. Luo, W. Zhang, G. Zhang, J. Guan, and X. Chen Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis Clin Exp Pharmacol Physiol 26 1999 903 908
26. H. Oral, N. Sivasubramanian, D.B. Dyke, R.H. Mehta, P.M. Grossman, and K. Briesmiester Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation Circulation 107 2003 831 837
27. M. Weis, S. Pehlivanli, B.M. Meiser, and W. Sheidt Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation J Am Coll Cardiol 38 2001 814 818
28. M. Aikawa, E. Rabkin, Y. Okada, S.J. Voglic, S.K. Clinton, and C.E. Brinckerhoff Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization Circulation 97 1998 2433 2444